Clinical Trial to Assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients
NCT ID: NCT05226897
Last Updated: 2022-06-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
256 participants
INTERVENTIONAL
2021-07-12
2023-06-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01 Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000 mg, and to Evaluate the Effect of Food on the Pharmacokinetics of DA-1229_01 in Healthy Male Volunteers
NCT02167061
A Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01(Evogliptin/Metformin XR 2.5/500 mg x 2 Tablets) Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000 mg in Healthy Male Volunteers
NCT02375139
A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin Alone
NCT04255238
The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes.
NCT04634500
The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin
NCT05505994
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Test
Take YYC405-T and Metformin≥1000mg, Dapagliflozin 10mg
YYC405-T
Subjects take the investigational products once a day for 24 weeks.
Metformin≥1000mg
Subjects take the investigational products once a day for 24 weeks.
Dapagliflozin 10mg
Subjects take the investigational products once a day for 24 weeks.
Placebo control
Take YYC405-T Placebo and Metformin≥1000mg, Dapagliflozin 10mg
Metformin≥1000mg
Subjects take the investigational products once a day for 24 weeks.
Dapagliflozin 10mg
Subjects take the investigational products once a day for 24 weeks.
YYC405-T placebo
Microcrystalline cellulose, Subjects take the investigational products once a day for 24 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
YYC405-T
Subjects take the investigational products once a day for 24 weeks.
Metformin≥1000mg
Subjects take the investigational products once a day for 24 weeks.
Dapagliflozin 10mg
Subjects take the investigational products once a day for 24 weeks.
YYC405-T placebo
Microcrystalline cellulose, Subjects take the investigational products once a day for 24 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A man or woman over 20 years old
* Type 2 Diabetes patients
Exclusion Criteria
* Type 1 diabetes patients
* Patients with a history of acute or chronic target acidosis, including lactic acidosis and diabetic ketoacidosis
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yooyoung Pharmaceutical Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sungrae Kim, MD, Ph.D
Role: STUDY_CHAIR
Bucheon St Mary Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Catholic University of Korea(Bucheon St. Mary's Hospital)
Bucheon-si, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YYPCT_YYC405_301
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.